Adherence to this guidance will not ensure successful treatment in every situation and should not be 23 deemed inclusive of all proper methods of care or exclusive of other methods reasonably directed to 24 obtaining the same results. The physician must make the ultimate judgment regarding any specific 25 therapy in light of all circumstances presented by the patient. ASTRO assumes no liability for the 26 information, conclusions, and findings contained in its papers. This guidance cannot be assumed to apply 27 to the use of these interventions performed in the context of clinical trials. 28
This guidance is based on information available at the time the task force conducted its research and 29 discussions on this topic. There may be new developments that are not reflected in this guidance and that 30 may, over time, be a basis for ASTRO to revisit and update the paper. 31
Introduction 79

Background 80
Comprehensive identification and delineation of organs-at-risk (OAR) are vital to the quality of radiation 81 therapy treatment planning and the safety of treatment delivery. A lack of standardization for normal 82 tissue contouring allows variation in practice and potentially impacts the quality of the dosimetric plan. 83
Advances made in the field of radiation oncology over the past decades include increased dose 84 conformality, particularly as the profession moved from two-dimensional (2-D) to three-dimensional (3-85 D) to intensity-modulated techniques. Improvements in the shaping and delivering of radiation have 86 yielded two major outcomes: improved avoidance of critical structures and dose intensification. When 87 targeting tumors, there may be adjacent structures for which potential toxicities are considered 88 unacceptable. Additionally, there are structures for which clinical decision-making can be affected by 89 toxicity risk depending on the disease site, patient age, treatment technique, prior radiation, and other 90 variables. Achieving plan optimization and maximal organ-sparing ultimately depends on the accuracy of 91 OAR definition and delineation. 92
This guidance aims to improve the consistency of contouring OARs by providing a single standardized 93 resource for information regarding specific OARs to be contoured for each disease site. 94
Scope 95
The Task Force organized the recommendations into a user-friendly table format as a quality assurance 96 tool for practices and a training resource for residents and other radiation oncology students. 97
• Table 1 contains two designations for anatomic sites: (1) Recommended -those structures that are 98 recommended for all cases based on consensus and (2) Consider -those structures that should be 99 considered depending on the specific clinical scenario. Understanding that practices and patients 100 need the best outcomes given possible resource constraints, the recommended list is focused on 101 the essential organs needed for each primary site to provide a basic minimum standard of care.
102
The organs listed in the consider category build on the recommended list and represent options 103 relevant to specific clinical situations. In both categories, the focus on structures has centered 104 around only those organs with recognized dose limits. Despite the importance of contouring and potential sources of variation, no recommended quality systems 169 exist to ensure accuracy and consistency in normal anatomy contouring. Standardization may allow better 170 quantification of DVH-toxicity relationships and assist in preventing avoidable toxicities to normal 171 structures. Failure to include OARs in the planning process may lead to "dose-dumping," where 172 unnecessary and potentially unsafe radiation doses are delivered to OARs that are not defined as part of 173 the planning constraints. This concept extends to the palliative setting, where doses to OARs are generally 174 considered less critical due to lower radiation doses and shorter patient life expectancy. Increasingly, re-175 irradiation is common, and if normal tissue doses are not tracked, inadvertent toxicity may occur. 176
Pre-treatment Preparation 177
Physician documentation 178
Constraining OARs is a fundamental component of the treatment planning process and should be 179 included in the radiation oncologist's pre-treatment planning directive (order) documented prior to the 180 initiation of treatment planning. The written planning directive must provide sufficient information to 181 guide qualified personnel in carrying out the creation of a treatment plan. 
Resources 193
Tools 194
Contouring guides, or atlases, are published for different anatomical sites to guide practitioners to define 195 clinical target volumes (CTV) and should also be used for visualization of tissue parameters. Disease site-196 specific contouring atlases published by NRG Oncology are commonly utilized and are developed via 197 consensus among cooperative groups and disease-site committees. Aside from the NRG Atlases, other 198 prominent sources exist, as published in radiation oncology journals. These tools should be used to 199 support consistency in practice procedures, for teaching resources, and in situations when planning 200 treatment for an uncommon or infrequently treated disease site. These contouring tools promise to reduce time, improve consistency, and increase quality; however, 240 structures generated from computer-based tools should always be subject to a manual review and 241 adjustment prior to initiating treatment planning. 242
243
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Treatment Planning Processes 245
Registration 246
Changes in anatomy due to possible tumor extension mandate a basic understanding of normal anatomy.
247
To assist with delineating normal tissues, imaging considerations are also important. Certain OARs are 248 better visualized or defined on contrast-enhanced CT scans or magnetic resonance imaging (MRI) scans, 249 compared to CT scans alone. For example, it is easier to delineate the parotid gland on a contrast CT due 250 to the enhancing nature of the organ. Similarly, to accurately delineate the spinal cord, particularly for 251 stereotactic planning, a high-resolution T2-weighted MRI or CT myelogram should be used. In the brain, 252 it may be easier to delineate the optic chiasm and nerves using a fused high-resolution T1-or T2-253 weighted MRI than a typical treatment-planning CT. Contrast-enhanced CT scans or specific sequences in 254 MRI scans for contouring facilitate delineation of normal tissues from adjacent tumor volumes and more 255 adequately spare OARs compared with non-contrast treatment planning CT scans. Any registration 256 should be verified before contouring commences. 257
Segmentation 258
Contouring appropriate OARs is essential for treatment planning, especially in the modern era of 259 modulated techniques where specific details regarding tissue parameters are a necessary component. Each 260 organ has its own best practice for appropriate contouring. For example, for lung constraints in the setting 261 of definitive radiation therapy for lung cancer, tumor target volumes (e.g., GTV or CTV) are usually 262 subtracted from the OAR volume to assess for dose constraints. Conversely, in the setting of CNS tumors, 263
there is no such subtraction of tumor target volumes for brainstem dose constraints. There may also be a 264 trade-off between adequate tissue sparing and optimal treatment of the target due to tumor location. 265
In developing guidance for appropriate organ contouring, the roles of artificial devices and surgical 266 interventions in treatment planning also were reviewed. Aside from anatomical region-specific examples, some universal suggestions are relevant regardless of 277 disease site. This list is not meant to be exhaustive, but it represents some general guiding principles: 278
• Contour on appropriate density windows (i.e., bone, lung) for each tissue.
279
• Create structure set templates in the TPS to set standard practice procedures. 280
• Use contrast-enhanced scans when relevant to assist with delineation. Large areas of contrast 281 need a density override or a registered non-contrast scan for planning purposes. 282
• Fuse relevant imaging (MRI, contrast-enhanced CT) to the planning CT to assist with tissue 283 definition, and always review final contouring on the primary data set. 284
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• Review structures in the coronal and sagittal planes when contouring on axial slices to verify 285 completeness of coverage in all dimensions. 286
Treatment plan optimization and evaluation 287
Incorrect contours may result in difficulties with plan optimization for inverse planning or multileaf 288 collimator (MLC) placement in forward-planned techniques. Ultimately, an error in any planning phase 289 may have a downstream consequence resulting in a suboptimal plan producing suboptimal patient 290 outcomes. 291
In accepting radiation therapy plans, a key step in the process is plan review and 3-D dose-volume-292 outcome analysis. Whether a more meaningful outcome for an OAR is the mean, maximum, or 293 volumetric dose, inherent in the interpretation of that metric is the assumption that the contours represent 294 the OAR. If not, the entire dosimetric treatment plan may be compromised, as treatment design aspects 295 including beam angle, location of static beams, and avoidance regions in arcs may be affected. By using a 296 standard set of tissues contoured based on disease site, evaluation of DVH data can be analyzed 297 confidently. 298
Summary 299
Standardization improves patient safety, efficiency, and accuracy in radiation oncology treatment. This 300 consensus guidance represents an ASTRO quality initiative to provide recommendations for the 301 standardization of normal tissue contouring performed during treatment planning for each anatomical 302 treatment site. Table 1 defines two sets of structures for anatomic sites: (1) those that are recommended in 303 all cases and (2) those that should be considered on a case-by-case basis depending on the specific clinical 304 scenario. Table 2 outlines the resources available for defined parameters for general organs-at-risk tissue 305 delineation. Using this paper in conjunction with resources defining tissue parameters and published dose 306 constraints will enable practices to develop a consistent approach to normal tissue evaluation. 307
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